Galectins comprise a family of soluble β-galactoside binding proteins, which regulate key biological processes including cell growth, differentiation, apoptosis, and immune responses.
Sixteen galectin genes have been identified in animal kingdoms, 12 of which are expressed in humans.Galectins are typically divided into three groups based on their structural characteristics: (i) prototypical galectins (Galectin-1 (Gal1), Gal2, Gal5, Gal7, Gal10, Gal11, Gal 13, Gal14, and Gal15), which are characterized by asingle CRD and can function as monomers or form homodimers; (ii) the chimeric galectin Gal3 (the only member of this class), which has asingle CRD and a Galectins have recently been linked to important therapeutic factors that affect whether a variety of anticancer treatment modalities, such as chemotherapy, radiotherapy, targeted therapies, antiangiogenic therapies, and immunotherapies are effective or ineffective.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V74909 | DB21, Galectin-1 Antagonist | 1623027-80-4 | DB21, Galectin-1 Antagonist is a dibenzofuran-conjugated peptide mimetic that works as an allosteric inhibitor of galectin-1 (GAL1) binding to cell surface glycans. | |
V76994 | G3-C12 TFA | G3-C12 (TFA) is a galectin-3 binding peptide with Kd of 88 nM and has anti-tumor activity. | ||
V74910 | Galectin-3 antagonist 1 | 2921603-03-2 | Galectin-3 antagonist 1 (compound 15) is a potent and specific Galectin-3 (Gal-3) antagonist (inhibitor) with a Kd of 5.3 μM. | |
V74911 | Galectin-3 antagonist 2 | 2921603-02-1 | Galectin-3 is a β-galactoside-specific carbohydrate recognition protein (lectin) that has the ability to promote the migration of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) cells and withstand drug treatment. | |
V74912 | Galectin-3-IN-2 | 2883648-71-1 | Galectin-3-IN-2 (Compound 9) is a potent multivalent galectin-3 (Gal-3; IC50=8.3 μM) inhibitor. | |
V79555 | Galectin-3/galectin-8-IN-1 | Galectin-3/galectin-8-IN-1 (Compound 53) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with K d values of 4.12 μM and 6.04 μM, respectively. | ||
V79556 | Galectin-3/galectin-8-IN-2 | Galectin-3/galectin-8-IN-2 (Compound 57) is a dual galectin-3 and galectin-8 C-terminal domain inhibitor (antagonist) with Kds of 12.8 μM and 2.06 μM, respectively. | ||
V80258 | Galectin-8-IN-1 | Galectin-8-IN-1 is a selective ligand of galectin-8N, with a Kd of 48 μM. | ||
V74913 | Galectin-8N-IN-1 | 2667628-25-1 | Galectin-8N-IN-1 (compound 19a) is a potent and specific galectin-8N inhibitor (antagonist) with a Kd of 1.8 μM. | |
V21523 | GB1107 | 1978336-61-6 | GB1107 (GB-1107) is a novel, potent, selective, orally bioavailable galectin-3 (GAL-3) inhibitor with anticancer activity. | |
V15975 | TD-139 | 1450824-22-2 | TD-139 is a novel and potent galectin-3 inhibitor with the potential for the treatment of idiopathic pulmonary fibrosis (IPF) | |
V74907 | Thiodigalactoside (TDG) | 51555-87-4 | Thiodigalactoside (TDG) is an orally bioactive and potent galectin (GAL) inhibitor (antagonist) with Kds of 24 μM and 49 μM for GAL-1 and GAL-3, respectively. |